Corvus Capital Exercises Pre-Funded Warrants, Takes 43.7% Stake in CDT Equity
CDT is trading near its 52-week low of $0.9 (2.8% above the low).
Summary
Corvus Capital, led by CEO Andrew Regan, exercised pre-funded warrants for 5.44 million shares, raising its stake to 43.7% of CDT Equity. The cashless exercise follows stockholder approval and deepens insider control amid the company's ongoing cash crisis.
Key Events · Ownership and Investor Activity · CDT
-
Corvus Exercises All Pre-Funded Warrants
On August 28, 2026, Corvus Capital Ltd. exercised all of its pre-funded warrants via cashless exercise, receiving 5,436,540 shares of CDT Equity common stock.
-
Stake Rises to 43.7%
Corvus now beneficially owns 5,693,706 shares, representing 43.7% of the 13,043,866 shares outstanding as of August 31, 2026.
-
Stockholder Approval Preceded Exercise
The exercise followed stockholder approval at the August 28, 2026 special meeting, which authorized issuance of shares upon exercise of the pre-funded warrants.
-
Cashless Exercise — No New Capital
The exercise was cashless, meaning Corvus received shares without paying cash; the company received no new funding from this transaction.
Analysis · CDT · Life Sciences
Corvus Capital Ltd., controlled by CEO Andrew Regan, exercised all of its pre-funded warrants on August 28, 2026, receiving 5,436,540 shares of CDT Equity common stock. This brings Corvus's total beneficial ownership to 5,693,706 shares, or 43.7% of the 13,043,866 shares outstanding. The exercise follows stockholder approval at the August 28 special meeting and completes a transaction first disclosed on July 31, 2026. The move consolidates insider control at a time when CDT Equity faces severe financial distress — cash down to $747K, a going concern warning, and a 1-for-10 reverse split enacted in July to maintain Nasdaq listing. The exercise was cashless, meaning no new capital entered the company; instead, Corvus converted its Sarborg Limited stake into a dominant equity position in CDT.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $0.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $715.9K. The 52-week trading range was $0.90 to $2,719.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.